Stem-cell transplantation in children with acute lymphoblastic leukemia:A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1265-1274

  Peters, Christina ^a   Matthes Martin, Susanne ^a   Poetschger, Ulrike ^a   Schrappe, Martin ^b   Schrauder, André ^c   Von Stackelberg, Arend ^d   Ebell, Wolfram ^d   Bader, Peter ^e   Klingebiel, Thomas ^e   Lang, Peter ^f   Sykora, Karl Walter ^g   Zimmerman, Martin ^g   Schrum, Johanna ^h   Kremens, Bernhard ⁱ   Ehlert, Karoline ^j   Albert, Michael H ^k   Meisel, Roland ^l   Holter, Wolfgang ^m   Strahm, Brigitte ⁿ   Gruhn, Bernd ^o   Schulz, Ansgar ^p   Woessmann, Wilhelm ^q   Gungor, Tayfun ^r   more..

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY OF KIEL   (Germany)

^c Kinderarztpraxis am Aalborgring   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^m UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o JENA UNIVERSITY HOSPITAL   (Germany)

^p UNIVERSITY HOSPITAL ULM   (Germany)

^q UNIVERSITY HOSPITAL GIESSEN   (Germany)

^r UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; HLA ANTIGEN; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; DISEASE SEVERITY; DONOR SELECTION; EVENT FREE SURVIVAL; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INCIDENCE; INFANT; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING DONOR; TREATMENT OUTCOME; UNRELATED DONORS; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EUROPE; GENETICS; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVING DONOR; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; SIBLING; TIME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; ETOPOSIDE; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LIVING DONORS; MALE; MYELOABLATIVE AGONISTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SIBLINGS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; WHOLE-BODY IRRADIATION;

EID: 84927151650     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.9747     Document Type: Article

References (46)

1. Schrappe M, Hunger SP, Pui CH, et al: Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366:1371-1381, 2012
2. von Stackelberg A, Völzke E, Kühl JS, et al: Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer 47:90-97, 2011
3. Ishaqi MK, Afzal S, Dupuis A, et al: Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant 41: 245-252, 2008
4. Walker T, Milford E, Chell J, et al: The National Marrow Donor Program: Improving access to hematopoietic cell transplantation. Clin Transpl 2011:55-62, 2011
5. Harvey J, Green A, Cornish J, et al: Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of highresolution matching at HLA class I and II. Bone Marrow Transplant 47:1294-1300, 2012
6. Zhang MJ, Davies SM, Camitta BM, et al: Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 18:1204-1210, 2012
7. Smith AR, Baker KS, Defor TE, et al: Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: Similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transplant 15:1086-1093, 2009
8. Pinkel D: 'Allogeneic marrow transplantation in children with acute leukemia: A practice whose time has gone': twenty years later. Leukemia 23: 2189-2196, 2009
9. Hahn T, Wall D, Camitta B, et al: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 11:823-861, 2005
10. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010
11. Krentz S, Hof J, Mendioroz A, et al: Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 27:295-304, 2013
12. Pulsipher MA, Peters C, Pui CH: High-risk pediatric acute lymphoblastic leukemia: To transplant or not to transplant? Biol Blood Marrow Transplant 17:S137-S148, 2011
13. Mann G, Attarbaschi A, Schrappe M, et al: Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: Results from the Interfant-99 Study. Blood 116:2644-2650, 2010
14. Dopfer R, Henze G, Bender-Götze C, et al: Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: Results of the German Cooperative Study. Blood 78:2780-2784, 1991
15. Matthes-Martin S, Lion T, Aberle SW, et al: Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: The impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 31:803-808, 2003
16. Locatelli F, Zecca M, Rondelli R, et al: Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 95:1572-1579, 2000
17. Möricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010
18. Tallen G, Ratei R, Mann G, et al: Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90. J Clin Oncol 28:2339-2347, 2010
19. Schrauder A, von Stackelberg A, Schrappe M, et al: Allogeneic hematopoietic SCT in children with ALL: Current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 41:S71-S74, 2008
20. Eapen M, Horowitz MM, Klein JP, et al: Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 22:4872-4880, 2004
21. Peters C, Cornish JM, Parikh SH, et al: Stem cell source and outcome after hematopoietic stem cell transplantation (HSCT) in children and adolescents with acute leukemia. Pediatr Clin North Am 57:27-46, 2010
22. Shimoni A, Bielorai B, Toren A, et al: Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity. Exp Hematol 31:428-434, 2003
23. Altman DG, Machin D, Bryant TN, et al: Statistics With Confidence: Confidence Intervals and Statistical Guidelines (ed 2). London, United Kingdom, BMJ Books
24. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
25. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
26. Andersen PK, Perme MP: Pseudo-observations in survival analysis. Stat Methods Med Res 19:71-99, 2010
27. Dini G, Zecca M, Balduzzi A, et al: No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood 118:6683-6690, 2011
28. Shaw PJ, Kan F, Woo Ahn K, et al: Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 116:4007-4015, 2010
29. Tracey J, Zhang MJ, Thiel E, et al: Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 19:255-259, 2013
30. Eckert C, von Stackelberg A, Seeger K, et al: Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia: Long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer 49:1346-1355, 2013
31. Davies SM, Wang D, Wang T, et al: Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 15:360-366, 2009
32. Mateos MK, O'Brien TA, Oswald C, et al: Transplant-related mortality following allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review. Pediatr Blood Cancer 60:1520-1527, 2013
33. Petersdorf EW, Hansen JA, Martin PJ, et al: Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345:1794-1800, 2001.
34. Flomenberg N, Baxter-Lowe LA, Confer D, et al: Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104:1923-1930, 2004
35. Veys P, Wynn RF, Ahn KW, et al: Impact of immune modulation with in vivo T-cell depletion and myeloablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 119: 6155-6161, 2012
36. MacMillan ML, Davies SM, Nelson GO, et al: Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 14:16-22, 2008
37. Remberger M, Mattsson J, Hentschke P, et al: The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. Bone Marrow Transplant 30:761-768, 2002
38. Gassas A, Sung L, Saunders EF, et al: Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: Significantly lower relapse rate in unrelated transplantations. Bone Marrow Transplant 40:951-955, 2007
39. Eckert C, Henze G, Seeger K, et al: Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 31:2736-2742, 2013
40. Bader P, Kreyenberg H, von Stackelberg A, et al: Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: Results of the ALL-BFM-SCT 2003 trial. J Clin Oncol 33:1275-1264, 2015
41. Baker KS, Ness KK, Weisdorf D, et al: Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study. Leukemia 24:2039-2047, 2010
42. Rizzo JD, Curtis RE, Socié G, et al: Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175-1183, 2009
43. Socié G, Baker KS, Bhatia S: Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant 18:S139-S150, 2012
44. Felicetti F, Manicone R, Corrias A, et al: Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: A retrospective study from a single institution. J Cancer Res Clin Oncol 137:1343-1348, 2011
45. Ricardi U, Filippi AR, Biasin E, et al: Late toxicity in children undergoing hematopoietic stem cell transplantation with TBI-containing conditioning regimens for hematological malignancies. Strahlenther Onkol 185:17-20, 2009
46. Bailey HK, Kappy MS, Giller RH, et al: Time-course and risk factors of hypothyroidism following allogeneic hematopoietic stem cell transplantation (HSCT) in children conditioned with fractionated total body irradiation. Pediatr Blood Cancer 51:405-409, 2008